Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 14/04/2015 Decision-making on FP7 work programmes and calls European Commission Research and Inovation DG, Directorate F Health Grigorij Kogan EKHA Meeting,

Similar presentations


Presentation on theme: "1 14/04/2015 Decision-making on FP7 work programmes and calls European Commission Research and Inovation DG, Directorate F Health Grigorij Kogan EKHA Meeting,"— Presentation transcript:

1 1 14/04/2015 Decision-making on FP7 work programmes and calls European Commission Research and Inovation DG, Directorate F Health Grigorij Kogan EKHA Meeting, Brussels 23/01/2012

2 2 14/04/2015 EU support for Research and Innovation The €50 billion Seventh Framework Programme (FP7, ) supports basic and applied research activities, still far from the market, offers money and concentrates resources on strategic research areas, always on the basis of technological and scientific excellence. The broad objectives of FP7 have been grouped into four categories: Cooperation Ideas People Capacities For each type of objective, there is a specific programme corresponding to the main areas of EU research policy. All specific programmes work together to promote and encourage the creation of European poles of (scientific) excellence

3 3 14/04/2015 FP7 budget ( ): €55 billion = ~6% of public R&D investment in Europe

4 4 14/04/2015 Cooperation programme: thematic areas (€32.4 billion)

5 5 14/04/2015

6 6 14/04/2015 FP7 Health Programme - structure pillar 1: Biotechnology, generic tools & technologies for health pillar 3: Optimising the delivery of health care cross-cutting issues: child health, the health of ageing population gender-related health issues pillar 2: Translating research for human health Activity (Pillar) 4: Other actions across the theme

7 7 14/04/2015 Collaborative research in the Health theme Main policy drivers:  Improving health of European citizens  Increasing competitiveness of European health- related industries and businesses  Addressing global health issues, including emerging epidemics

8 8 14/04/2015 Collaborative research at European level across borders and other barriers ● between countries:  multinational consortia, with at least 3 partners from 27 EU Member States (MS) and / or Associated Countries (AC) e.g.: Albania, Croatia, FYR Macedonia, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey.  researchers from any country in the world can participate, from industrialised countries and from developing countries. e.g.: Argentina, Australia, Brazil, Canada, China, India, Japan, Korea, New-Zealand, Russia, South-Africa, USA… ● between different types of organizations Public & private sector: universities, research centres, large companies, Small and medium-sized enterprises (SMEs), etc. ● between disciplines: multidisciplinary, translational

9 9 14/04/2015 Collaborative research in the Health theme 1: Biotechnology, generic tools and technologies  High-throughput research  Detection, diagnosis and monitoring  Predicting suitability, safety and efficacy of therapies  Innovative therapeutic approaches and interventions

10 10 14/04/2015 Collaborative research in the Health theme 2: Translating research for human health  Integrating biological data and processes: large-scale data gathering, systems biology  Research on the brain and related diseases, human development and ageing  Translational research in major infectious diseases  Translational research in other major diseases

11 11 14/04/2015 Collaborative research in the Health theme 3: Optimising the delivery of healthcare  Translating clinical research into clinical practice  Quality, efficiency and solidarity of healthcare systems  Enhanced health promotion and disease prevention

12 12 14/04/ Actions across the Theme  Coordination & Support Actions across the theme  Responding to EU policy needs  Specific International Cooperation Actions (SICAs) Collaborative research in the Health theme

13 13 14/04/2015 FP7 Cooperation Work Programme: Health-2012

14 14 14/04/2015 Two-stage submission and evaluation procedure Timetable Publication of call FP7-HEALTH-2012-INNOVATION-220 July 2011 Deadline for submission of stage 1 outline proposals27 September 2011 Evaluation of stage 1 outline proposalsOctober 2011 ESRs sent to outline proposal coordinators (“initial information letters”, including invitation letters to successful applicants) November 4, 2011 Deadline for submission of stage 2 full proposals13 December 2011 Evaluation of stage 2 full proposalsJanuary 2012 Ethical screeningBy February 3, 2012 Invitation letter to successful coordinators to launch grant agreement negotiations with Commission services By February, 2012 Negotiation kick-off meeting in BrusselsFebruary 13, 2012 Signature of first grant agreementsApril 2012

15 15 14/04/2015 Funding schemes in the Health theme Funding schemes limits partners Large-scale integrating project (CP-IP)≥ €6m ≤ €12m ≥3 Network of Excellence (NoE)≤ €12m ≥3 Small- or medium-scale focussed research project (CP-FP)≤ €3m or €6m ≥3 Coordination action (CA)*≤ €1.5m ≥3 Support action (SA)*≤ €0.5m ≥1 * for CAs and SAs there are some exceptions.

16 16 14/04/2015 Emphasis and special measures for: Small & Medium-sized Enterprises (SMEs)  Opportunities and support measures International Cooperation  the possibility to tackle issues on a global scale  an opportunity to extend networks beyond Europe Policy dimensions: Industry (SME) participation & International Cooperation

17 17 14/04/2015 Who prepares the work programmes for the Research Priorities ● The EU Commission  Collects ideas for the preparation of the annual FP7 work program  Drafts the (annual) FP7 work plans  Within the EU Commission Scientific Officers (SO) are responsible for the preparatory work o Advisory Groups (AG)  Have been set up by the EU Commission for each of the FP7 themes  They provide consistent, consolidated advice for the work program  Members sit on the AG in their personal capacity and do not represent any organisation or country o National Contact Points (NCPs)  Are main providers of advice and individual assistance in all Member States and Associated States  Have been set up by the Member or Associated States so the type and level of services offered may differ from country to country o Programme Committees (PCs)  Play an important role at the end of the preparation process of each work program.  They have to give their approval for all the work programmes that have been prepared by he EU Commission.  Are involved quite early in the preparation process to insure that the preparation procedure works quick and smooth

18 18 14/04/2015 Scientific excellence at European level From policy to funding the best research projects: ● The policy for Health research is described in the FP7 specific programme (available on CORDIS ● Each year, a work programme is prepared by the EC, in consultation with a scientific Advisory Group and with the Programme Committee ● Through calls for proposals the EC invites researchers from all Europe and beyond to submit their proposals ● The very best projects are selected on the basis of evaluation by independent experts (peer review) ● After negotiation of a grant agreement, a project is funded for 2- 5 years

19 19 14/04/2015 Submission & evaluation Basic principles: annual calls for proposals eligibility (scope, partners, funding limits, deadline) evaluation by panels of independent experts  overseen by Independent Observers 3 criteria:  Science & Technology excellence  Implementation & Management  Potential Impact feedback: Evaluation Summary Reports (ESRs)

20 20 14/04/2015 Annual calls for proposals in the Health Theme  1 st call (2007 budget): € 641 million  2 nd call (2008 budget): € 577 million  3 rd call (2009 budget): € 610 million  4 th call (2010 budget): € 660 million  5 th call (2011 budget): € 650 million  6 th call (2012 budget): ~ € 645 million  7 th call (2013 budget): ~

21 21 14/04/ The Innovative Medicines Initiative (IMI): the Largest PPP in Life Sciences R&D Why Public-Private Partnership? Innovative medicines require in-depth knowledge of disease pathways and molecular targets Anticipating potential side effects of new drugs is a must The pharmaceutical industry builds new business models based on collaboration and transparency Key Concepts Underlying IMI Projects: Pre-competitive research Open innovation Four Calls published since 2008: 23 projects funded Over € 450 million committed

22 22 14/04/2015 Coverage of Kidney Diseases in FP7 Pillar IDEAS – ERC (European Research Council): 4 projects with € 6,813,200 EU Contribution Pillar COOPERATION - HEALTH: 7 projects with € 46,188,148 EU Contribution INFSO: 2 projects with € 8,759,140 EU Contribution Pillar PEOPLE – 13 projects with € 9,872,575 EU Contribution Total EU Contribution - € 71,633,063

23 23 14/04/2015

24 24 14/04/2015 Contacts & Information FP7 Health web site: NCPs: Registration as an Expert: https://cordis.europa.eu/emmfp7/ FP7 calls: Health projects database: SMEsgoHealth:

25 25 14/04/2015 The Health Directorate Director – Dr. Ruxandra Draghia-Akli: Medical Research unit (F2) Head of unit: Maria Vidal-Ragout Deputy Head of Unit: Karim Berkouk Infectious Diseases unit (F3) Head of unit: Line Mathiessen Deputy Head of unit: Anna Lönnroth Avanced Therapies and Systems Medicine unit (F4) Head of unit: Arnd Hoeveler ) Deputy Head of unit: Bernard Mulligan Personalized Medicine unit (F5) Head of unit: Patrik Kolar ) Deputy Head of unit: Irene Norstedt Administration & Finance unit (F6) Head of unit: Georgios Zisimatos Horizontal Aspects unit (F1) Head of unit: Stéphane Hogan

26 26 14/04/2015 What is Horizon 2020

27 27 14/04/2015 THANK YOU FOR YOUR ATTENTION! Grigorij Kogan « Chronic Diseases » Unit F-2 Medical Research Directorate F « Health » DG Research and Innovation European Commission


Download ppt "1 14/04/2015 Decision-making on FP7 work programmes and calls European Commission Research and Inovation DG, Directorate F Health Grigorij Kogan EKHA Meeting,"

Similar presentations


Ads by Google